DEBRA Research gGmbH
Goethestrasse 52, Munich, Bayern, 80336, Germany
Overview
DEBRA Research is a non-profit organization that serves as the research arm of DEBRA Austria and operates globally. Its primary focus is on translational research and clinical development aimed at creating therapies and eventual cures for Epidermolysis Bullosa (EB), a rare and debilitating genetic skin disorder that causes extreme skin fragility, blistering, and chronic wounds. mission is to identify, promote, fund, and manage the most promising research projects to alleviate symptoms and ultimately cure EB
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 1
Sector focus
- Biotechnology
- Clinical Trials
- Non Profit
- Pharmaceutical
- Product Research
Investment portfolio
- Mariposa Therapeutics
Participated · Seed · Mar 2026
Mariposa Therapeutics is developing MP5219 as a potential first-in-class, disease-modifying therapy for Epidermolysis Bullosa Simplex (EBS), a chronic genetic condition that causes skin to blister and tear. The company plans to use the seed funding to carry out pre-clinical development, secure scientific advice, and engage early with regulators ahead of clinical progression. It intends to establish a Cardiff research facility with laboratory space in 2026 and to recruit scientific staff in Wales to support formulation development and future manufacturing. Leadership includes CEO Dr David Howat (appointed October 2024) and chief scientific officer Dr Lucy Sykes. Financially, Mariposa completed a £750,000 seed round led by the Development Bank of Wales with co-investment from DEBRA Research gGmbH and the founders, positioning the company to pursue further funding for clinical development.
Team
Christoph Coch
LinkedIn